MarketPulse

DCCR drug candidate

4 articles
BenzingaBenzinga··The Law Offices Of Frank R. Cruz

SLNO Shareholders Sue Over Alleged Safety Disclosure Failures in PWS Drug Trial

Soleno Therapeutics faces securities fraud lawsuit alleging failure to disclose safety concerns about DCCR drug candidate between March 2025 and November 2026.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Securities Lawsuit Over Undisclosed Safety Risks in DCCR Trial

Rosen Law Firm files class action against Soleno Therapeutics for allegedly concealing fluid retention safety concerns in DCCR clinical trials, affecting drug viability.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Soleno Therapeutics Faces Securities Lawsuit Over DCCR Safety Disclosures

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors must claim lead plaintiff status by May 5, 2026.
SLNOstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Soleno Therapeutics Faces Securities Fraud Probe Over Undisclosed Safety Data

Law firm probing Soleno Therapeutics for allegedly concealing safety data on drug DCCR. Investors must file claims by May 5, 2026.
SLNOstock declinesecurities class action